Abstracts tagged "spondyloarthritis"

Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Nelly Ziade¹, Karen Mechleb², Nizar Ani³, avin maroof⁴, ASAL ADNAN RIDHA⁵, Manal El Rakawi⁶, Chafika Haouichat⁶, Bassel Elzorkany⁷, Sherif Gamal⁸, Mariama Erraoui⁹, Manal Al-Mashaleh¹⁰, Fatima Alnaimat¹¹, Basel masri¹², fatemah Baron¹³, Lina El Kibbi¹⁴, Krystel Aouad¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH - ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Baghdad College of Medicine, Baghdad, Iraq, ⁴University of Kurdistan Hawler, Erbil, Iraq, ⁵Baghdad Teaching Hospital, baghdad, Iraq, ⁶Djillali Bounaama University Hospital, Algiers, Algeria, ⁷Private (BZRC), Cairo, Egypt, ⁸Cairo University, Cairo, Egypt, ⁹Souss Massa Univeristy, Rabat, Morocco, ¹⁰Royal Medical Services, Amman, Jordan, ¹¹University of Jordan, Amman, Jordan, ¹²Jordan Hospital and Medical Center, Amman, Jordan, ¹³Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹⁴Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁵Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…
Abstract Number: 2362 • ACR Convergence 2024
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Lianne S Gensler¹, Helena Marzo-Ortega², Vanessa Taieb³, Diana Voiniciuc⁴, Alexander Marten⁵, George Stojan⁶, Mindy Kim⁶ and Martin Rudwaleit⁷, ¹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³UCB Pharma, Colombes, France, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Atlanta, GA, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ has demonstrated sustained efficacy and safety to Week…
Abstract Number: 0077 • ACR Convergence 2024
Characteristics of Axial Spondyloarthritis in Patients with Onset Chronic Low Back Pain After Age 45
Fatma Zohra Yasmina Heddi¹, Zahira Lamri², kheireddine khelif², Amina Benammar² and wafa Zahdour², ¹Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Oran, Algeria, ²Oran University Hospital, Rheumatology Department/ University of Oran 1, Faculty of Medicine, Oran, Algeria
Background/Purpose: The onset of axial spondyloarthritis (axSpA), as defined by the Assessment of SpondyloArthritis International Society (ASAS) criteria is unusual after the age of 45…
Abstract Number: 0543 • ACR Convergence 2024
Impact of Peripheral Manifestations on Function, Health, and Work Productivity in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study
Clementina López Medina¹, Anna Molto², Dafne Capelusnik³ and Sofia Ramiro⁴, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral musculoskeletal manifestations can occur either concomitantly with axial disease or independently in patients with spondyloarthritis (SpA). However, it is not known whether the…
Abstract Number: 0563 • ACR Convergence 2024
Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort
Manouk de hOoge¹, Pedro M. Machado², Sytske Anne Bergstra³, Maxime Dougados⁴, Clementina López Medina⁵, Victoria Navarro Compán⁶, Diego Benavent⁷, Denis Poddubnyy⁸, Levent kilic⁹, Philippe Carron¹⁰, Dirk Elewaut¹¹, Filip Van den Bosch¹² and Gaelle Varkas¹², ¹Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, ²Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³LUMC, Leiden, Netherlands, ⁴Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ⁸Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁹Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ¹⁰UZ Gent, Gent, Belgium, ¹¹Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹²Ghent University Hospital, Ghent, Belgium
Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
Abstract Number: 0592 • ACR Convergence 2024
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Helena Marzo-Ortega¹, Philip Mease², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Martin Rudwaleit⁶, Maria Antonietta D'Agostino⁷, Christine de la Loge⁸, Ute Massow⁹, Vanessa Taieb¹⁰, Diana Voiniciuc¹¹ and Atul Deodhar¹², ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Colombes, France, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In the phase 3 studies, BE MOBILE 1 and 2, bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to…
Abstract Number: 1117 • ACR Convergence 2024
JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review
Nuria Barroso Garcia¹, Lara Sanchez Bilbao², Jose Luis Martin Varillas³, Vanesa Calvo-Rio⁴, Mar Esteban Ortega⁵, Santiago muñoz Fernández⁵, Jose Luis álvarez Vega⁶, Emma Beltran Catalan⁷, Vega Jovani⁸, Olga Maiz Alonso⁹, Raúl Veroz González¹⁰, Carmen Alvarez Reguera¹¹, Rosalia Demetrio Pablo¹² and Ricardo Blanco-Alonso¹³, ¹Rheumatology, Hospital Regional Universitario, Universidad de Málaga UMA, Málaga, Spain, Malaga, Spain, ²Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology. Hospital de Laredo. IDIVAL, Immunopathology Group. Laredo, Spain, Santander, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Rheumatology and Ophthalmology. Hospital Infanta Sofía, Madrid. Spain, Madrid, Spain, ⁶Rheumatology. Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, Badajoz, Spain, ⁷Rheumatology. Hospital del Mar. Barcelona, Spain, Barcelona, Spain, ⁸National Health system, Alicante, Spain, ⁹Rheumatology. Hospital de Donostia. San Sebastián, Spain, San Sebastián, Spain, ¹⁰Hospital Mérida, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Rheumatology and Ophthalmology. Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group. Santander. Spain, Santander, Spain, ¹³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Non-infectious uveitis refractory to conventional immunosuppressants and even biologic therapy can lead to severe ocular conditions. Janus Kinase inhibitors (JAKINIBs) appear to be effective…
Abstract Number: 1468 • ACR Convergence 2024
Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
Diego Benavent¹, Victoria Navarro Compán², Dafne Capelusnik³ and Sofia Ramiro⁴, ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
Abstract Number: 1936 • ACR Convergence 2024
Referral and Diagnostic Delays of Patients with Chronic Inflammatory Rheumatic Diseases: A Cross-sectional Study in Eight Countries
Nelly Ziade¹, Nizar Ani², avin maroof³, ASAL ADNAN RIDHA⁴, Manal El Rakawi⁵, Chafika Haouichat⁵, Bassel Elzorkany⁶, Sherif Gamal⁷, Mariama Erraoui⁸, Manal Al-Mashaleh⁹, Fatima Alnaimat¹⁰, Basel masri¹¹, fatemah Baron¹², Lina El Kibbi¹³, Krystel Aouad¹⁴, Karen Mechleb¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Baghdad College of Medicine, Baghdad, Iraq, ³University of Kurdistan Hawler, Erbil, Iraq, ⁴Baghdad Teaching Hospital, baghdad, Iraq, ⁵Djillali Bounaama University Hospital, Algiers, Algeria, ⁶Private (BZRC), Cairo, Egypt, ⁷Cairo University, Cairo, Egypt, ⁸Souss Massa Univeristy, Rabat, Morocco, ⁹Royal Medical Services, Amman, Jordan, ¹⁰The University of Jordan, amman, Jordan, ¹¹Jordan Hospital and Medical Center, Amman, Jordan, ¹²Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹³Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁴Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁵Saint Joseph University Beirut, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRDs) may benefit from a critical window of opportunity for early intervention, yet referral delays remain a major…
Abstract Number: 2363 • ACR Convergence 2024
“How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Atul Deodhar¹, Elena Nikiphorou², Abhijeet Danve³, Stephen Hall⁴, Vanessa Taieb⁵, Diana Voiniciuc⁶, Marina Magrey⁷ and Xenofon Baraliakos⁸, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²King's College London, London, United Kingdom, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Cabrini Medical Centre, Monash University, and Emeritus Research, Melbourne, Victoria, Australia, ⁵UCB Pharma, Colombes, France, ⁶UCB Pharma, Slough, United Kingdom, ⁷Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Two phase 3 studies were conducted where treatment…
Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0544 • ACR Convergence 2024
A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
Ana Bento da Silva¹, Sofia Ramiro², Miranda van Lunteren¹, Mary Lucy Marques³, Marleen Van De Sande⁴, Camilla Fongen⁵, Sofia Exarchou⁶, Roberta Ramonda⁷, Desiree van der Heijde⁸ and Floris van Gaalen⁹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Bunde, Netherlands, ³Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, ⁴Amsterdam Institute for Infection & Immunity and Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Lund University, Åkarp, Sweden, ⁷Rheumatology Unit, University of Padova, Italy, Padova, Italy, ⁸Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁹LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) frequently leads to reduced spinal and hip mobility, though evidence pertains mostly to patients with longstanding disease and radiographic damage. More…
Abstract Number: 0564 • ACR Convergence 2024
The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Mayas Arraf¹, Devy Zisman², walid Saliba³, Nili Stein⁴ and Joy Feld⁵, ¹Technion medical school, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel medical center, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
Abstract Number: 0597 • ACR Convergence 2024
Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Fabian Proft¹, Desiree van der Heijde², Sergio Schwartzman³, Joerg Ermann⁴, Alexander Marten⁵, Ute Massow⁵, George Stojan⁶, Vanessa Taieb⁷, Diana Voiniciuc⁸, Astrid van Tubergen⁹, Victoria Navarro Compán¹⁰ and Xenofon Baraliakos¹¹, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, Hospital for Special Surgery, New York, NY, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Atlanta, GA, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Slough, United Kingdom, ⁹Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ¹⁰La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ¹¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease requiring optimal management. Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) and ASAS partial remission (ASAS…
Abstract Number: 1389 • ACR Convergence 2024
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Amy Peeters¹, Maike Wientjes², Wieland Müskens¹, David Ten Cate³, Bart van den Bemt⁴, Noortje van Herwaarden¹ and Alfons den Broeder², ¹Sint maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Since the compound patent on the bio-originator of adalimumab expired, several adalimumab biosimilars (BS) have been introduced. Extensive research shows equivalence in effectiveness and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].